BRIEF published on 05/23/2024 at 11:40, 1 year 8 months ago Crossing thresholds for GENSIGHT BIOLOGICS SA Actions Crossing Thresholds GenSight Biologics Armistice Capital Subscription Warrants
PRESS RELEASE published on 05/23/2024 at 11:35, 1 year 8 months ago Franchissement de seuils Déclaration de franchissement de seuils par Armistice Capital, LLC concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris Euronext Paris Franchissement De Seuils Armistice Capital LLC GENSIGHT BIOLOGICS SA Déclaration Régularisation
BRIEF published on 05/07/2024 at 19:34, 1 year 9 months ago GenSight Biologics Announces Availability of Prospectus for New Shares Listing on Euronext Paris Euronext Paris Capital Increase Gene Therapy Prospectus GenSight Biologics
BRIEF published on 05/07/2024 at 19:34, 1 year 9 months ago GenSight Biologics annonce la mise à disposition d'un prospectus pour la cotation de nouvelles actions sur Euronext Paris Euronext Paris Augmentation De Capital Thérapie Génique Prospectus Produits Biologiques GenSight
PRESS RELEASE published on 05/07/2024 at 19:29, 1 year 9 months ago Terms of availability of prospectuses GenSight Biologics announces availability of listing prospectus for new shares on Euronext Paris. The prospectus approved by AMF includes universal registration document, securities note, and summary Euronext Paris New Shares AMF Approval GenSight Biologics Listing Prospectus
PRESS RELEASE published on 05/07/2024 at 19:29, 1 year 9 months ago Modalités de mise à disposition de prospectus GenSight Biologics annonce la mise à disposition d'un prospectus pour l'admission d'actions nouvelles sur Euronext Paris. La société spécialisée dans les thérapies géniques pour les maladies neurodégénératives informe sur le processus Euronext Paris Prospectus GenSight Biologics Thérapies Géniques Maladies Neurodégénératives
Published on 02/21/2026 at 00:45, 18 hours 30 minutes ago Bocana Resources Corp. Extends Letter of Intent on Arizona Mining Claims for Additional Bulk Testing and Assay Review
Published on 02/21/2026 at 00:30, 18 hours 45 minutes ago Redwood AI Corp. Announces Engagement for IR Services
Published on 02/20/2026 at 23:00, 20 hours 15 minutes ago Infinico Metals Corp. Announces Effective Date for 15-for-1 Common Share Consolidation
Published on 02/20/2026 at 22:17, 20 hours 58 minutes ago Organto Foods Completes Warrant Exercise Incentive Program
Published on 02/21/2026 at 12:00, 7 hours 15 minutes ago Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Published on 02/21/2026 at 12:00, 7 hours 15 minutes ago Abivax présente, au Congrès de l’ECCO 2026, les premières preuves d’une activité antifibrotique d'obefazimod, ainsi que de nouvelles analyses de son efficacité et de sécurité dans les MICI
Published on 02/20/2026 at 18:36, 1 day ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 19:29, 23 hours 45 minutes ago SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 19:29, 23 hours 45 minutes ago SFPI GROUP: bilan du contrat de liquidité S2 S025
